{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:24:44Z","timestamp":1777785884715,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jcv.2022.105273","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T06:22:31Z","timestamp":1661926951000},"page":"105273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection"],"prefix":"10.1016","volume":"156","author":[{"given":"Samuel SM","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris KP","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John KC","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna S","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosco HS","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trushar","family":"Jeevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Kandeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pekosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl CK","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo CH","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny W","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo LH","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken KP","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Webby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo LM","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David SC","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-5995","authenticated-orcid":false,"given":"Malik","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2022.105273_bib0001","article-title":"Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants","author":"Altarawneh","year":"2022","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.jcv.2022.105273_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6608","key":"10.1016\/j.jcv.2022.105273_bib0003","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.abq0203","article-title":"Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines","volume":"377","author":"Bowen","year":"2022","journal-title":"Science"},{"issue":"7923","key":"10.1016\/j.jcv.2022.105273_bib0004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.jcv.2022.105273_bib0005","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.jcv.2022.105273_bib0006","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.18.2200178","article-title":"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022","volume":"27","author":"Cheng","year":"2022","journal-title":"Euro Surveill."},{"issue":"3","key":"10.1016\/j.jcv.2022.105273_bib0007","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcv.2022.105273_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2022.07.002","article-title":"SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns","author":"Gruell","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jcv.2022.105273_bib0009","article-title":"Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5","author":"Hachmann","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jcv.2022.105273_bib0010","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1038\/s41467-022-32396-9","article-title":"Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection","volume":"13","author":"Khan","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jcv.2022.105273_bib0011","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcv.2022.105273_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101174","article-title":"Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection","volume":"41","author":"Lau","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"24","key":"10.1016\/j.jcv.2022.105273_bib0013","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2022.105273_bib0014","series-title":"Proc Natl Acad Sci USA","first-page":"7001","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020"},{"key":"10.1016\/j.jcv.2022.105273_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","author":"McMenamin","year":"2022","journal-title":"Lancet Inf. Dis."},{"key":"10.1016\/j.jcv.2022.105273_bib0016","unstructured":"New York State Department of Health (2022). New York State Department of Health Announces Emergence of Recently Identified, Highly Contagious Omicron Subvariants in New York and Urges Continued Vigilance Against COVID-19."},{"issue":"7818","key":"10.1016\/j.jcv.2022.105273_bib0017","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2022.105273_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","author":"Tegally","year":"2022","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.jcv.2022.105273_bib0019","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"issue":"7902","key":"10.1016\/j.jcv.2022.105273_bib0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2022.105273_bib0021","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2022.105273_bib0022","unstructured":"WHO. (2021, 26 November 2021). \"Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern.\"."},{"issue":"4","key":"10.1016\/j.jcv.2022.105273_bib0023","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect. Dis."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653222002050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653222002050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:16:26Z","timestamp":1761362186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653222002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"alternative-id":["S1386653222002050"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2022.105273","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2022.105273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105273"}}